<DOC>
	<DOCNO>NCT02920424</DOCNO>
	<brief_summary>The purpose study assess safety tolerability JNJ-56022473 follow multiple subcutaneous ( SC ) study agent administration subject Systemic Lupus Erythematosus ( SLE ) determine whether premedication corticosteroid require improve tolerability SC JNJ-56022473 .</brief_summary>
	<brief_title>A Study Evaluate Safety , Pharmacokinetics , Pharmacodynamics JNJ-56022473 Subjects With Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Subject must body weight range 40 100 kilogram ( kg ) , inclusive , body mass index ( BMI ) 18 32 kilogram per meter square ( kg/m^2 ) , inclusive , screen Subjects eligible enrollment study must qualify follow : ) must meet Systemic Lupus International Collaborating Clinics ( SLICC ) criteria diagnosis lupus b ) must least one nonserologic clinical activity define Systemic Lupus Erythematosus Disease Activity Index 2000 ( SLEDAI2K ) within 3 month prior first study agent administration Have positive gene signature score screening , prior first administration study agent Subjects use allow preexist lupus treatment , stable least 6 week prior first dose study medication : 1. oral corticosteroid equivalent average dose equal ( &lt; = ) 10 milligram ( mg ) prednisone/day 2. use antimalarial ( chloroquine hydroxychloroguine ) least 8 week 3. maximum 1 noncorticosteroid immunosuppressive drug Subject history suspect occurrence druginduced systemic lupus erythematosus ( SLE ) Subject unstable lupus nephritis and/ active Central nervous system ( CNS ) lupus history severe CNS lupus , include limited seizure , psychosis , transverse myelitis , CNS vasculitis optic neuritis Major surgery prior , , plan , shortly study eligible Subject acute illness , include common cold , within 2 week prior study agent administration major illness hospitalization within 4 month prior screen visit Any inflammatory disease might confound evaluation efficacy exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>